Multiple sclerosis (MS) has devastating physical, psychological, and economic
consequences. The disease commences in most patients with a relapsing-remitting course …

Although the earliest recorded description of multiple sclerosis (MS) dates back to the 14 th
century, it was not until the latter years of the 20 th that treatments for this disabling condition …

Multiple sclerosis (MS) has emerged as a treatable disorder with several disease-modifying
therapies (DMTs) now licensed in the United States for MS treatment. These are interferon …

In recent years, the usefulness of interferon beta and glatiramer acetate in the treatment of
relapsing-remitting multiple sclerosis (RRMS) has been established. Interferon beta has also …

The field of multiple sclerosis entered the treatment era in 1993, over a decade ago, and
now enjoys the availability of five marketed disease-modifying agents. This is an enviable …

Because MS is chronic and often debilitating, with an indefinite etiology and variable
pathology, it is a diagnostic and management challenge for most clinicians. MS is usually …

The treatment of MS with immunomodulatory agents such as interferon beta and glatiramer
acetate, early in the disease course, is increasingly recognized as benefiting patient …

Clearly, MS can be associated with a host of burdensome, and sometimes progressive,
symptoms. The therapeutic options for MS have been greatly enhanced over the past …

Opinion statement Multiple sclerosis (MS) is likely an autoimmune disorder, although this
remains unproven. Immunotherapeutic treatments have been shown to be helpful …

Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system characterized by demyelination and axonal loss. The etiology of MS is unknown; …